The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

Science

Volumn 322, Issue 5905, 2008, Pages 1211-1217

  Jaakola, Veli Pekka ^a   Griffith, Mark T ^a   Hanson, Michael A ^a   Cherezov, Vadim ^a   Chien, Ellen Y T ^a   Lane, J Robert ^b   Ijzerman, Adriaan P ^b   Stevens, Raymond C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONIST; CAFFEINE; DISULFIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; RHODOPSIN;

CRYSTAL STRUCTURE; PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TRIAZOLES; TRYPTOPHAN; TURKEYS;

EID: 56749103466     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1164772     Document Type: Article

References (61)

1. B. B. Fredholm, J. F. Chen, S. A. Masino, J. M. Vaugeois, Annu. Rev. Pharmacol. Toxicol. 45, 385 (2005).
2. B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K. N. Klotz, J. Linden, Pharmacol. Rev. 53, 527 (2001).
3. T. V. Dunwiddie, S. A. Masino, Annu. Rev. Neurosci. 24, 31 (2001).
4. K. A. Jacobson, Z. G. Gao, Nat. Rev. Drug Discov. 5, 247 (2006).
5. J. Sawynok, X. J. Liu, Prog. Neurobiol. 69, 313 (2003).
6. Y. Shi et al., J. Cereb. Blood Flow Metab. 28, 111 (2008).
7. M. A. Schwarzschild, L. Agnati, K. Fuxe, J. F. Chen, M. Morelli, Trends Neurosci. 29, 647 (2006).
8. S. Lahiri, C. H. Mitchell, D. Reigada, A. Roy, N. S. Cherniack, Respir. Physiol. Neurobiol. 157, 123 (2007).
9. R. Basheer, R. E. Strecker, M. M. Thakkar, R. W. McCarley, Prog. Neurobiol. 73, 379 (2004).
10. M. A. Hernan, B. Takkouche, F. Caamano-Isorna, J. J. Gestal-Otero, Ann. Neurol. 52, 276 (2002).
11. S. Ferre, J. Neurochem. 105, 1067 (2008).
12. S. Ferre et al., Front. Biosci. 13, 2391 (2008).
13. A. H. Schapira et al., Nat. Rev. Drug Discov. 5, 845 (2006).
14. D. Blum, R. Hourez, M. C. Galas, P. Popoli, S. N. Schiffmann, Lancet Neurol. 2, 366 (2003).
15. R. A. Brown, D. Spina, C. P. Page, Br. J. Pharmacol. 153, (suppl. 1), S446 (2008).
16. M. J. During, D. D. Spencer, Ann. Neurol. 32, 618 (1992).
17. E. E. Benarroch, Neurology 70, 231 (2008).
18. E. Ongini, S. Dionisotti, S. Gessi, E. Irenius, B. B. Fredholm, Naunyn Schmiedebergs Arch. Pharmacol. 359, 7 (1999).
19. S. M. Poucher et al., Br. J. Pharmacol. 115, 1096 (1995).
20. B. E. Cohen et al., Proc. Natl. Acad. Sci. U.S.A. 102, 965 (2005).
21. B. K. Kobilka, X. Deupi, Trends Pharmacol. Sci. 28, 397 (2007).
22. V. P. Jaakola, J. Prilusky, J. L. Sussman, A. Goldman, Protein Eng. Des. Sel. 18, 103 (2005).
23. S. G. Rasmussen et al., Nature 450, 383 (2007).
24. D. M. Rosenbaum et al., Science 318, 1266 (2007).
25. F. Magnani, Y. Shibata, M. J. Serrano-Vega, C. G. Tate, Proc. Natl. Acad. Sci. U.S.A. 105, 10744 (2008).
26. M. J. Serrano-Vega, F. Magnani, Y. Shibata, C. G. Tate, Proc. Natl. Acad. Sci. U.S.A. 105, 877 (2008).
27. V. Cherezov et al., Science 318, 1258 (2007).
28. C. K. Engel, L. Chen, G. G. Prive, Biochim. Biophys. Acta 1564, 38 (2002).
29. Materials and methods are available as supporting material on Science Online.
30. M. A. Hanson et al., Structure 16, 897 (2008).
31. 2A-WT refers to the wild-type construct without T4L. All constructs have a FLAG purification tag in the amino terminus and 10 histidine residues in the carboxy terminus.
32. Z. G. Gao, A. P. IJzerman, Biochem. Pharmacol. 60, 669 (2000).
33. 2A primary sequence (accession number P29274). Note: In addition to numbering residue positions in the primary amino acid sequence, the residues have numbers in superscripts (X.YY) that indicate their position in each transmembrane helix (X, helix number, from 1 to 8), relative to the most conserved reference residue in that helix (YY). This residue is arbitrarily assigned the number 50; numbers decrease toward the N terminus and increase toward the C terminus. However, the numbering is not used in loop regions beyond residues X.20 and/or X.80 or T4L.
34. 2AR-T4L constructs that were solved in different space groups.
35. M. Murakami, T. Kouyama, Nature 453, 363 (2008).
36. K. Palczewski et al., Science 289, 739 (2000).
37. T. Warne et al., Nature 454, 486 (2008).
38. A. Martinelli, T. Tuccinardi, Med. Res. Rev. 28, 247 (2008).
39. O. Yuzlenko, K. Kiec-Kononowicz, J. Comput. Chem., 21 May 2008, 10.1002/jcc.21001, in press.
40. P. Joost, A. Methner, Genome Biol. 3, RESEARCH0063 (2002).
41. D. K. Vassilatis et al., Proc. Natl. Acad. Sci. U.S.A. 100, 4903 (2003).
42. The FatCat server (http://fatcat.burnham.org/) was used for structural alignment of the transmembrane helices with the rhodopsin structure 1U19 as a reference taken directly from that server: "It simultaneously addresses the two major goals of flexible structure alignment; optimizing the alignment and minimizing the number of rigid-body movements (twists) around pivot points (hinges) introduced in the reference structure."
43. G. S. Ratnaparkhi, R. Varadarajan, Biochemistry 39, 12365 (2000).
44. We used the program Occluded Surface (OS) that calculates the occluded surface and atomic packing of protein model structures: www.csb.yale.edu/ userguides/datamanip/os/.
45. It has been speculated that the general activation mechanism include following changes 6.47 (gauche + conformer) / 6.48 (trans - conformer) / 6.52 (trans - conformer) represent the active state (R*) and 6.47 (trans - conformer) / 6.48 (gauche + conformer) / 6.52 (gauche + conformer) represent inactive state (R).
46. D. L. Farrens, C. Altenbach, K. Yang, W. L. Hubbell, H. G. Khorana, Science 274, 768 (1996).
47. Basal or constitutive activity is the spontaneous production of cellular response in the absence of a ligand. An inverse agonist shifts the equilibrium toward the inactive state. An agonist shifts the conformation toward the active state. A (neutral) antagonist binds to receptors and blocks the active site but does not shift the equilibrium. A typical GPCR can "dial" almost any conformational equilibrium between fully inactive and fully active; therefore, an agonist or inverse agonist can be classified as partial to full. Depending on receptor and cellular environment, the nature of an inverse agonist and a truly neutral antagonist can be difficult to detect.
48. R. Vogel et al., J. Mol. Biol. 380, 648 (2008).
49. T. Okada et al., J. Mol. Biol. 342, 571 (2004).
50. E. S. Burstein, T. A. Spalding, M. R. Brann, J. Biol. Chem. 273, 24322 (1998).
51. L. Birnbaumer, F. O. Levy, X. Zhu, A. J. Kaumann, Tex. Heart Inst. J. 21, 16 (1994).
52. J. Zezula, M. Freissmuth, Br. J. Pharmacol. 153 (suppl. 1), S184 (2008).
53. D. J. Scholl, J. N. Wells, Biochem. Pharmacol. 60, 1647 (2000).
54. J. Kim et al., Mol. Pharmacol. 49, 683 (1996).
55. J. Kim, J. Wess, A. M. van Rhee, T. Schoneberg, K. A. Jacobson, J. Biol. Chem. 270, 13987 (1995).
56. S. Moro et al., Chem. Commun. (Camb.) 2949 (2003).
57. M. De Zwart et al., Drug Dev. Res. 48, 95 (1999).
58. M. Mantri et al., J. Med. Chem. 51, 4449 (2008).
59. Q. Jiang, B. X. Lee, M. Glashofer, A. M. van Rhee, K. A. Jacobson, J. Med. Chem. 40, 2588 (1997).
60. M. Audet, M. Bouvier, Nat. Chem. Biol. 4, 397 (2008).
61. 2A receptor.